Analyst Conference Summaries

Biotechnology Investor Aids


conference date: February 14, 2018 @ 5:00 AM Pacific Time

Bioverativ Target Raised on 10-K Data [Seeking Alpha, March 27, 2017]

Bioverativ Should have a Strong Launch [January 10, 2017 @ Seeking Alpha]

Note: BIVV started trading on February 1, 2017.

May 4, 2017
August 3, 2017
Oct. 27, 2017
Feb. 14, 2017

Bioverativ (BIVV) is a commercial-stage biotechnology company specializing in hemophilia therapies and developing therapies for other blood disorders. It was spun off from Biogen (BIIB).

Bioverativ web site



More Analyst Conference Pages:


Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.

Copyright 2017 William P. Meyers